Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Moving beyond anatomy: the future of rectal cancer management is biologically-informed, response-adapted, and patient-centered.

Clinical and translational radiation oncology·2026

Same author

Long-term patient-reported outcomes in a randomized controlled trial of Mepitel Film versus standard of care for the prevention of acute breast radiation dermatitis.

Breast cancer research and treatment·2026

Same author

Dose-de-escalated focal radiotherapy for primary cutaneous T-cell lymphoma: a lesion-based retrospective cohort study.

Acta oncologica (Stockholm, Sweden)·2026

Same author

Dose dE-eScalaTion IN prostATe radIOtherapy usiNg an MR-Linac in 2 Fractions (DESTINATION 2): protocol for a randomised, phase II/R-IDEAL2b trial.

BMJ open·2026

Same author

Prognostic value of DICER and CA9 expression in patients with anal squamous cell carcinoma treated with definitive chemoradiotherapy.

European journal of cancer (Oxford, England : 1990)·2026

Same author

[Neoadjuvant chemotherapy versus chemoradiotherapy in rectal cancer without involvement of the mesorectal fascia-Implications of CONVERT for radiation oncology?]

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Potentiating Salvage Radiotherapy in Radiorecurrent Prostate Cancer Through Anti-CTLA4 Therapy: Implications from a

Hanzhi Wang^1,2, Linsey Gong¹, Xiaoyong Huang²

¹Department of Medical Biophysics, University of Toronto, Toronto, ON M5S 1L7, Canada.

|August 29, 2024

Summary

Combining radiation therapy (RT) with anti-CTLA4 immunotherapy significantly delays tumor growth and cures some mice with recurrent prostate cancer (PCa). This approach enhances T-cell responses in the tumor microenvironment.

Keywords:

anti-CTLA4 brachytherapy prostate cancer radiorecurrence radiotherapy

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Related Experiment Videos

Last Updated: Jun 16, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Area of Science:

Oncology
Immunotherapy
Radiation Oncology

Background:

High-risk prostate cancer (PCa) poses a significant mortality risk.
Local disease recurrence after radiation therapy (RT) presents a major clinical challenge.
Immune checkpoint inhibitors (ICIs) show promise with ionizing radiation (IR) in other cancers.

Purpose of the Study:

To evaluate the efficacy of ICIs combined with RT in a preclinical model of radiorecurrent PCa.
To investigate the impact of anti-PDL1 and anti-CTLA4 in combination with IR.

Main Methods:

Generation of the TRAMP-C2 HF radiorecurrent syngeneic mouse model.
Treatment with anti-PDL1, anti-CTLA4, IR, or combinations thereof.
Analysis of tumor growth delay and immune cell populations (T cells) in tumor-draining lymph nodes and tumors.

Main Results:

Neither anti-PDL1 nor anti-CTLA4 monotherapy significantly delayed tumor growth.
Combination of IR and anti-PDL1 showed no additional benefit over IR alone.
Combination of IR and anti-CTLA4 resulted in significant tumor growth delay and complete cure in one-third of mice.
IR plus anti-CTLA4 upregulated T-cell function genes and increased CD4+ and CD8+ T-cell populations.

Conclusions:

IR combined with anti-CTLA4 immunotherapy demonstrates significant therapeutic potential in radiorecurrent prostate cancer.
This combination enhances anti-tumor T-cell responses, offering a promising strategy for treating recurrent disease.